Essex Investment Management Co. LLC Has $934,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Essex Investment Management Co. LLC lessened its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 11.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 125,417 shares of the company’s stock after selling 16,727 shares during the period. Essex Investment Management Co. LLC owned about 0.18% of EyePoint Pharmaceuticals worth $934,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. GSA Capital Partners LLP boosted its position in EyePoint Pharmaceuticals by 129.6% during the 3rd quarter. GSA Capital Partners LLP now owns 32,979 shares of the company’s stock worth $264,000 after acquiring an additional 18,616 shares during the period. Intech Investment Management LLC bought a new stake in EyePoint Pharmaceuticals during the 3rd quarter valued at approximately $136,000. Charles Schwab Investment Management Inc. grew its stake in shares of EyePoint Pharmaceuticals by 5.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock worth $1,141,000 after acquiring an additional 7,967 shares during the last quarter. Patient Square Capital LP acquired a new stake in EyePoint Pharmaceuticals in the 3rd quarter worth $10,882,000. Finally, Wellington Management Group LLP increased its stake in EyePoint Pharmaceuticals by 59.4% during the third quarter. Wellington Management Group LLP now owns 171,764 shares of the company’s stock valued at $1,372,000 after acquiring an additional 64,008 shares during the period. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Price Performance

EYPT opened at $7.13 on Monday. The company’s 50 day simple moving average is $7.25 and its 200-day simple moving average is $8.45. The stock has a market capitalization of $486.63 million, a P/E ratio of -3.57 and a beta of 1.41. EyePoint Pharmaceuticals, Inc. has a one year low of $5.54 and a one year high of $26.06.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The business had revenue of $11.60 million for the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. As a group, analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Robert W. Baird lowered their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. Citigroup began coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $33.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.